keyword
https://read.qxmd.com/read/37474262/deliberation-on-debilitating-condition-of-cancer-cachexia-skeletal-muscle-wasting
#21
REVIEW
Srusti Dave, Bhoomika M Patel
BACKGROUND: Cancer cachexia is a debilitating syndrome associated with marked body loss because of muscular atrophy and fat loss. There are several mechanisms contributing to the pathogenesis of cachexia. The presence of the tumor releases cytokines from inflammatory and immune cells, which play a significant role in activating and deactivating certain pathways associated with protein, carbohydrate, and lipid metabolism. This review focuses on various cascades involving an imbalance between protein synthesis and degradation in the skeletal muscles...
July 20, 2023: Fundamental & Clinical Pharmacology
https://read.qxmd.com/read/37438792/exercise-mitigates-dapagliflozin-induced-skeletal-muscle-atrophy-in-stz-induced-diabetic-rats
#22
JOURNAL ARTICLE
Xudong Yang, Lifeng Wang, Liangzhi Zhang, Xia Zhai, Xiusheng Sheng, Hengjun Lin, Helong Quan
BACKGROUND: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are commonly used in the management of type 2 diabetes mellitus (T2DM) and have been found to worsen the reduction of skeletal muscle mass in individuals with T2DM. This study aims to examine the potential of exercise in mitigating the skeletal muscle atrophy induced by SGLT2i treatment. METHODS: A rat model of T2DM (40 male Sprague-Dawley rats; T2DM induced by a combination of high-fat diet and streptozotocin) was used to examine the effects of six-week treatment with Dapagliflozin (DAPA, SGLT2i) in combination with either aerobic exercise (AE) or resistance training (RT) on skeletal muscle...
July 12, 2023: Diabetology & Metabolic Syndrome
https://read.qxmd.com/read/37428166/sarcopenia-in-end-stage-liver-disease-and-after-liver-transplantation
#23
REVIEW
S Leunis, M Vandecruys, A H Van Craenenbroeck, V Cornelissen, S Bogaerts, S De Smet, D Monbaliu
Sarcopenia occurs in 30-70% of patients with end-stage liver disease and is associated with inferior pre- and post-liver transplant outcomes such as prolonged intubation times, long intensive care and hospitalization times, heightened risk of post-transplant infection, reduced health-related quality of life, and increased rates of mortality. The pathogenesis of sarcopenia is multifactorial and involves biochemical disturbances such as hyperammonemia, low serum concentrations of branched-chain amino acids (BCAAs) and low serum levels of testosterone, as well as chronic inflammation, inadequate nutritional status, and physical inactivity...
2023: Acta Gastro-enterologica Belgica
https://read.qxmd.com/read/37367877/effect-of-genetically-reduced-maternal-myostatin-on-late-gestation-maternal-fetal-and-placental-metabolomes-in-mice
#24
JOURNAL ARTICLE
Ruth Opoku, Jenna DeCata, Charlotte L Phillips, Laura C Schulz
Myostatin (gene symbol: Mstn ) is an autocrine and paracrine inhibitor of muscle growth. Pregnant mice with genetically reduced levels of myostatin give birth to offspring with greater adult muscle mass and bone biomechanical strength. However, maternal myostatin is not detectable in fetal circulations. Fetal growth is dependent on the maternal environment, and the provisioning of nutrients and growth factors by the placenta. Thus, this study examined the effect of reduced maternal myostatin on maternal and fetal serum metabolomes, as well as the placental metabolome...
June 1, 2023: Metabolites
https://read.qxmd.com/read/37364546/effects-of-lenvatinib-on-skeletal-muscle-volume-and-cardiac-function-in-patients-with-hepatocellular-carcinoma
#25
JOURNAL ARTICLE
Hidenari Nagai, Makoto Amanuma, Takanori Mukozu, Kojiro Kobayashi, Hideki Nagumo, Kunihide Mohri, Go Watanabe, Naoyuki Yoshimine, Yu Ogino, Yasuko Daido, Yasushi Matsukiyo, Teppei Matsui, Noritaka Wakui, Koichi Momiyama, Koji Higai, Takahisa Matsuda, Yoshinori Igarashi
INTRODUCTION: previously, we reported that the tyrosine kinase inhibitor (TKI) sorafenib decreases serum levels of carnitine and reduce skeletal muscle volume. Moreover, others were reported that TKIs might lead to cardiomyopathy or heart failure. Therefore, this study aimed to evaluated the effects of lenvatinib (LEN) on skeletal muscle volume and cardiac function in patients with hepatocellular carcinoma (HCC). METHODS: This retrospective study included 58 adult Japanese patients with chronic liver diseases and HCC treated with LEN...
June 26, 2023: Oncology
https://read.qxmd.com/read/37348598/current-and-investigational-medications-for-the-treatment-of-sarcopenia
#26
REVIEW
Yves Rolland, Cedric Dray, Bruno Vellas, Philipe De Souto Barreto
Sarcopenia, defined as the loss of muscle mass and function, is a widely prevalent and severe condition in older adults. Since 2016, it is recognized as a disease. Strength exercise training and nutritional support are the frontline treatment of sarcopenia, with no drug currently approved for this indication. However, new therapeutic options are emerging. In this review, we evidenced that only very few trials have focused on sarcopenia/sarcopenic patients. Most drug trials were performed in different clinical older populations (e...
June 20, 2023: Metabolism: Clinical and Experimental
https://read.qxmd.com/read/37288303/myostatin-a-potential-therapeutic-target-for-metabolic-syndrome
#27
REVIEW
Ming Yang, Chongbin Liu, Na Jiang, Yan Liu, Shilu Luo, Chenrui Li, Hao Zhao, Yachun Han, Wei Chen, Li Li, Li Xiao, Lin Sun
Metabolic syndrome is a complex metabolic disorder, its main clinical manifestations are obesity, hyperglycemia, hypertension and hyperlipidemia. Although metabolic syndrome has been the focus of research in recent decades, it has been proposed that the occurrence and development of metabolic syndrome is related to pathophysiological processes such as insulin resistance, adipose tissue dysfunction and chronic inflammation, but there is still a lack of favorable clinical prevention and treatment measures for metabolic syndrome...
2023: Frontiers in Endocrinology
https://read.qxmd.com/read/37093948/comparison-of-growth-performance-and-related-gene-expression-of-muscle-and-fat-from-landrace-yorkshire-and-duroc-and-woori-black-pigs
#28
JOURNAL ARTICLE
Bosung Kim, Yejin Min, Yongdae Jeong, Sivasubramanian Ramani, Hyewon Lim, Yeonsu Jo, Woosang Kim, Yohan Choi, Sungkwon Park
The purpose of this study was to compare marbling score, meat quality, juiciness, sarcomere length, and skeletal muscle satellite cell (SMSC) growth and related gene expression between Woori black pig (WB) and the Landrace, Yorkshire, and Duroc (LYD) crossbreed at different body weights (b.w.). WB was developed to improve meat quality and growth efficiency by crossbreeding Duroc with Korean native black pig. A total of 24 pigs were sacrificed when their b.w. reached about 50, 75, 100, and 120 kg. SMSC were isolated from the femoris muscles, and muscle and adipose tissues were sampled from the middle and the subcutaneous part of the femoris of hind legs, respectively...
January 2023: Journal of Animal Science and Technology
https://read.qxmd.com/read/37016578/red-blood-cell-extracellular-vesicles-deliver-therapeutic-sirnas-to-skeletal-muscles-for-treatment-of-cancer-cachexia
#29
JOURNAL ARTICLE
Boya Peng, Yuqi Yang, Zhiyuan Wu, Rachel Tan, Thach Tuan Pham, Eric Yew Meng Yeo, Marco Pirisinu, Migara Kavishka Jayasinghe, Tin Chanh Pham, Kun Liang, Ng Shyh-Chang, Minh Tn Le
Cancer cachexia is a multifactorial syndrome characterized by a significant loss of skeletal muscle, that negatively affects the quality of life. Inhibition of myostatin (Mstn), a negative regulator of skeletal muscle growth and differentiation, has been proven to preserve muscle mass in muscle atrophy diseases, including cachexia. However, myostatin inhibitors have repeatedly failed clinical trials because of modest therapeutic effects and side effects due to the poor efficiency and toxicity of existing delivery methods...
April 3, 2023: Molecular Therapy
https://read.qxmd.com/read/36946003/myostatin-inhibitory-peptides-in-sports-drug-testing
#30
JOURNAL ARTICLE
Katja Walpurgis, Johannes Agricola, Andreas Thomas, Mario Thevis
Across species, skeletal muscle mass is negatively regulated by the TGF-β cytokine myostatin (MSTN). Inhibitors of this growth factor and its signaling pathways are therefore not only promising therapeutics for muscular diseases but also potential performance-enhancing agents in sports. Within this study, protein precipitation and liquid chromatography high-resolution tandem mass spectrometry (LC-HRMS/MS) were employed to develop a detection method for six novel MSTN inhibitory peptides derived from the regulatory MSTN propeptide and the natural MSTN inhibitor follistatin (FST) from doping control serum samples...
March 22, 2023: Drug Testing and Analysis
https://read.qxmd.com/read/36941755/network-pharmacology-based-pharmacokinetic-assessment-and-evaluation-of-the-therapeutic-potential-of-catechin-derivatives-as-a-potential-myostatin-inhibitor-a-special-view-on-sarcopenic-obesity
#31
JOURNAL ARTICLE
Sarvesh Sabarathinam, Satish Kumar Rajappan Chandra, Sanjana Satheesh
Sarcopenic obesity has become a significant age-related metabolic problem. Catechins are flavanol, derivatives which poses a strong antioxidant activity. The major components of catechin derivatives. were identified through our physicochemical and pharmacokinetic parameters estimation. Therefore, in this study, network pharmacology was used to explore the multiple targets related to Sarcopenia, Metabolic syndrome, and obesity. The targets were identified from network analysis. The catechin derivatives were screened using Lipinski's rule of five, Veber scale, Egan scale, and Muegge scale...
March 20, 2023: Natural Product Research
https://read.qxmd.com/read/36901894/myostatin-overexpression-and-smad-pathway-in-detrusor-derived-from-pediatric-patients-with-end-stage-lower-urinary-tract-dysfunction
#32
JOURNAL ARTICLE
Souzan Salemi, Larissa J Schori, Tim Gerwinn, Maya Horst, Daniel Eberli
Cell therapies and tissue engineering approaches using smooth muscle cells (SMCs) may provide treatment alternatives for end-stage lower urinary tract dysfunction (ESLUTD). Myostatin, a negative regulator of muscle mass, is a promising target to improve muscle function through tissue engineering. The ultimate goal of our project was to investigate the expression of myostatin and its potential impact in SMCs derived from healthy pediatric bladders and pediatric ESLUTD patients. Human bladder tissue samples were evaluated histologically, and SMCs were isolated and characterized...
February 24, 2023: International Journal of Molecular Sciences
https://read.qxmd.com/read/36810486/chronic-stress-induces-type-2b-skeletal-muscle-atrophy-via-the-inhibition-of-mtorc1-signaling-in-mice
#33
JOURNAL ARTICLE
Shigeko Fushimi, Tsutomu Nohno, Hironobu Katsuyama
Chronic stress induces psychological and physiological changes that may have negative sequelae for health and well-being. In this study, the skeletal muscles of male C57BL/6 mice subjected to repetitive water-immersion restraint stress to model chronic stress were examined. In chronically stressed mice, serum corticosterone levels significantly increased, whereas thymus volume and bone mineral density decreased. Further, body weight, skeletal muscle mass, and grip strength were significantly decreased. Histochemical analysis of the soleus muscles revealed a significant decrease in the cross-sectional area of type 2b muscle fibers...
February 10, 2023: Medical Sciences: Open Access Journal
https://read.qxmd.com/read/36773783/circulating-%C3%AE-klotho-counteracts-transforming-growth-factor-%C3%AE-induced-sarcopenia
#34
JOURNAL ARTICLE
Yutaka Ohsawa, Hideaki Ohtsubo, Asami Munekane, Kohei Ohkubo, Tatsufumi Murakami, Masahiro Fujino, Shin-Ichiro Nishimatsu, Hiroki Hagiwara, Hirotake Nishimura, Ryuki Kaneko, Takahiro Suzuki, Ryuichi Tatsumi, Wataru Mizunoya, Atsushi Hinohara, Masao Fukunaga, Yoshihide Sunada
α-Klotho is a longevity-related protein. Its deficiency shortens lifespan with prominent senescent phenotypes, including muscle atrophy and weakness in mice. α-Klotho has two forms: membrane α-Klotho and circulating α-Klotho (c-α-Klotho). Loss of membrane α-Klotho impairs a phosphaturic effect, thereby accelerating phosphate-induced aging. However, the mechanisms of senescence on c-α-Klotho loss remain largely unknown. Herein, with the aging of wild-type mice, c-α-Klotho declined, whereas Smad2, an intracellular transforming growth factor (TGF)-β effector, became activated in skeletal muscle...
May 2023: American Journal of Pathology
https://read.qxmd.com/read/36738276/challenges-and-future-prospects-of-targeting-myostatin-activin-a-signaling-to-treat-diseases-of-muscle-loss-and-metabolic-dysfunction
#35
JOURNAL ARTICLE
Se-Jin Lee, Shalender Bhasin, Lloyd Klickstein, Venkatesh Krishnan, Daniel Rooks
Over the past 25 years, considerable progress has been made in terms of elucidating the regulatory and signaling mechanisms underlying the control of skeletal muscle mass by myostatin and other secreted proteins belonging to the transforming growth factor-ß superfamily. Preclinical studies demonstrating the potential benefits of targeting the activities of these ligands have fueled the development of numerous biologics capable of perturbing this signaling pathway and increasing muscle mass and function...
February 4, 2023: Journals of Gerontology. Series A, Biological Sciences and Medical Sciences
https://read.qxmd.com/read/36700044/erratum-hmej-mediated-site-specific-integration-of-a-myostatin-inhibitor-increases-skeletal-muscle-mass-in-porcine
#36
Mengjing Li, Xiaochun Tang, Wenni You, Yanbing Wang, Yiwu Chen, Ying Liu, Hongming Yuan, Chuang Gao, Xue Chen, Zhiwei Xiao, Hongsheng Ouyang, Daxin Pang
[This corrects the article DOI: 10.1016/j.omtn.2021.06.011.].
March 14, 2023: Molecular Therapy. Nucleic Acids
https://read.qxmd.com/read/36646717/inhibiting-myostatin-signaling-partially-mitigates-structural-and-functional-adaptations-to-hindlimb-suspension-in-mice
#37
JOURNAL ARTICLE
Andrea M Hanson, Mary H Young, Brooke C Harrison, Xiaolan Zhou, H Q Han, Louis S Stodieck, Virginia L Ferguson
Novel treatments for muscle wasting are of significant value to patients with disease states that result in muscle weakness, injury recovery after immobilization and bed rest, and for astronauts participating in long-duration spaceflight. We utilized an anti-myostatin peptibody to evaluate how myostatin signaling contributes to muscle loss in hindlimb suspension. Male C57BL/6 mice were left non-suspended (NS) or were hindlimb suspended (HS) for 14 days and treated with a placebo vehicle (P) or anti-myostatin peptibody (D)...
January 16, 2023: NPJ Microgravity
https://read.qxmd.com/read/36430183/myostatin-knockout-affects-mitochondrial-function-by-inhibiting-the-ampk-sirt1-pgc1%C3%AE-pathway-in-skeletal-muscle
#38
JOURNAL ARTICLE
Mingjuan Gu, Zhuying Wei, Xueqiao Wang, Yang Gao, Dong Wang, Xuefei Liu, Chunling Bai, Guanghua Su, Lei Yang, Guangpeng Li
Myostatin ( Mstn ) is a major negative regulator of skeletal muscle mass and initiates multiple metabolic changes. The deletion of the Mstn gene in mice leads to reduced mitochondrial functions. However, the underlying regulatory mechanisms remain unclear. In this study, we used CRISPR/Cas9 to generate myostatin-knockout ( Mstn -KO) mice via pronuclear microinjection. Mstn -KO mice exhibited significantly larger skeletal muscles. Meanwhile, Mstn knockout regulated the organ weights of mice. Moreover, we found that Mstn knockout reduced the basal metabolic rate, muscle adenosine triphosphate (ATP) synthesis, activities of mitochondrial respiration chain complexes, tricarboxylic acid cycle (TCA) cycle, and thermogenesis...
November 8, 2022: International Journal of Molecular Sciences
https://read.qxmd.com/read/36336354/electrophoretic-detection-of-black-market-myostatin-propeptide
#39
JOURNAL ARTICLE
Christian Reichel, Günter Gmeiner, Mario Thevis
Myostatin propeptide is prohibited according to chapter S4 of the "WADA 2022 List of Prohibited Substances and Methods". So far, no approved myostatin-propeptide pharmaceuticals are available. Nevertheless, myostatin-propeptides can be bought on the black market for "research purposes". A study on black market myostatin propeptide products is presented as well as electrophoretic detection methods for serum and urine. Out of the twelve tested products, only nine actually contained the protein. Separation by SDS-PAGE revealed that the nine products were relatively impure and that the main compound had a much higher mass (ca...
November 6, 2022: Drug Testing and Analysis
https://read.qxmd.com/read/36266260/myostatin-a-skeletal-muscle-chalone
#40
REVIEW
Se-Jin Lee
Myostatin (GDF-8) was discovered 25 years ago as a new transforming growth factor-β family member that acts as a master regulator of skeletal muscle mass. Myostatin is made by skeletal myofibers, circulates in the blood, and acts back on myofibers to limit growth. Myostatin appears to have all of the salient properties of a chalone, which is a term proposed over a half century ago to describe hypothetical circulating, tissue-specific growth inhibitors that control tissue size. The elucidation of the molecular, cellular, and physiological mechanisms underlying myostatin activity suggests that myostatin functions as a negative feedback regulator of muscle mass and raises the question as to whether this type of chalone mechanism is unique to skeletal muscle or whether it also operates in other tissues...
February 10, 2023: Annual Review of Physiology
keyword
keyword
80455
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.